EUVIMEDEUVIMED entdecken
Crossref

The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7–H4 in lung adenocarcinoma harboring EGFR-activating mutants

Youwei Lu, Yu Sun, Jie Zhang, Miao Kong, Zhiming Zhao, Boshu Sun, Yuan Wang, Ying Jiang, Shaomu Chen, Chao Wang, Yin Tong, Liangzhu Wen und 3 weitere

Cancer Letters · 2024-08 · 596 · 217020

DOI: 10.1016/j.canlet.2024.217020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Youwei Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: ErbB Receptors, Ubiquitin Thiolesterase, V-Set Domain-Containing T-Cell Activation Inhibitor 1, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7-H4 is an immune checkpoint crucial for inhibiting CD8+ T-cell activity. A clinical trial is underway to investigate B7-H4 as a potential immunotherapeutic agent. However, the regulatory mechanism of B7-H4 degradation via the ubiquitin-proteasome pathway (UPP) remains poorly understood. In this study, we discovered that proteasome inhibitors effectively increased B7-H4 expression, while EGFR-activating mutants promoted B7-H4 expression through the UPP. We screened B7-H4 binding proteins by co-immunoprecipitation and mass spectrometry and found that USP2a acted as a deubiquitinase of B7-H4 by removing K48- and K63-linked ubiquitin chains from B7-H4, leading to a reduction in B7-H4 degradation. EGFR mutants enhanced B7-H4 stability by upregulating USP2a expression. We further investigated the role of USP2a in tumor growth in vivo. Depletion of USP2a in L858R/LLC cells inhibited tumor cell proliferation, consequently suppressing tumor growth in immune-deficient nude mice by destabilizing downstream molecules such as Cyclin D1. In an immune-competent C57BL/6 mouse tumor model, USP2a abrogation facilitated infiltration of CD95+CD8+ effector T cells and hindered infiltration of Tim-3+CD8+ and LAG-3+CD8+ exhausted T cells by destabilizing B7-H4. Clinical lung adenocarcinoma samples showed a significant correlation between B7-H4 abundance and USP2a expression, indicating the contribution of the EGFR/USP2a/B7-H4 axis to tumor immunosuppression. In summary, this study elucidates the dual effects of USP2a in tumor growth by stabilizing Cyclin D1, promoting tumor cell proliferation, and stabilizing B7-H4, contributing to tumor immunosuppression. Therefore, USP2a represents a potential target for tumor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsUbiquitin ThiolesteraseV-Set Domain-Containing T-Cell Activation Inhibitor 1Lung NeoplasmsAdenocarcinoma of LungMice, NudeAnimalsHumansMiceCell Line, TumorCell ProliferationMutationMice, Inbred C57BLCD8-Positive T-LymphocytesProteasome Endopeptidase Complex

Stichwörter der Autor:innen

B7–H4DeubiquitinationEGFR MTTumor immunosuppressionUSP2a

Substanzen

ErbB ReceptorsUbiquitin ThiolesteraseV-Set Domain-Containing T-Cell Activation Inhibitor 1EGFR protein, humanVTCN1 protein, humanUSP2 protein, humanProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
  • Department of Hematology, Shanghai Zhaxin Traditional Chinese and Western Medicine Hospital, Shanghai, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu, China.
  • Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • He Cheng Biotechnology Suzhou Co.Ltd, Suzhou, Jiangsu, China.

Zitieren

APA

Lu, Y., Sun, Y., Zhang, J., Kong, M., Zhao, Z., Sun, B., Wang, Y., Jiang, Y., Chen, S., Wang, C., Tong, Y., Wen, L., Huang, M., Wu, F., & Zhang, L. (2024). The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7–H4 in lung adenocarcinoma harboring EGFR-activating mutants. Cancer Letters, 596, 217020. https://doi.org/10.1016/j.canlet.2024.217020

Vancouver

Lu Y, Sun Y, Zhang J, Kong M, Zhao Z, Sun B, et al. The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7–H4 in lung adenocarcinoma harboring EGFR-activating mutants. Cancer Letters. 2024;596:217020. doi:10.1016/j.canlet.2024.217020

BibTeX
@article{Lu2024,
  author = {Lu, Youwei and Sun, Yu and Zhang, Jie and Kong, Miao and Zhao, Zhiming and Sun, Boshu and Wang, Yuan and Jiang, Ying and Chen, Shaomu and Wang, Chao and Tong, Yin and Wen, Liangzhu and Huang, Moli and Wu, Fengying and Zhang, Liang},
  title = {The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7–H4 in lung adenocarcinoma harboring EGFR-activating mutants},
  journal = {Cancer Letters},
  year = {2024},
  volume = {596},
  pages = {217020},
  doi = {10.1016/j.canlet.2024.217020}
}
Kostenlos starten →